The stock of BioLineRx Ltd. (NASDAQ:BLRX) decreased by -$0.01 on Wednesday to $1.32, down -0.75 percent. The last five days have seen an average of 771,582 shares of common stock traded. 23 times new highs were reached in the current year, with a gain of $0.7100. The average number of shares traded over the last 20 days was 557,340, while the average volume over the last 50 days totaled 421,866.
BLRX stock dropped -15.92% since last month. On 08/28/23, the company’s shares reached a one-month low of $1.2000. The stock touched a high of $1.82 on 06/13/23, after rallying from a low of $0.55 in 52 weeks. The price of BLRX stock has risen by 123.73% or $0.7100 this year, reaching a new high 23 times. Still, the stock price is down -27.47% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
For the three months ended March 30, BioLineRx Ltd.’s quick ratio was 3.70, while its current ratio was 3.70, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending March 30 is 0.25, and the total debt to equity ratio is 0.33. Based on annual data, it had gross profit of $2.16 million and revenue of $29.16 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BLRX’s return on assets (ROA) during the last 12 months has been -43.70%. In the meantime, the return on equity (ROE) for the last 12 months was -63.70%.
Earnings Surprise
According to BioLineRx Ltd.’s quarterly financial report for the quarter that ended March 30. A higher net income was reported in the quarter under review than the previous quarter. It was predicted that BioLineRx Ltd.’s quarterly earnings would be -$0.15, but it ended up being -$0.17, beating the consensus by 11.80%. EBITDA was -$8.6 million for the quarter. At the end of BioLineRx Ltd.’s most recent quarter ended March 30, its liabilities totaled 29.53 million, while its total debt was $12.88 million.
Technical Picture
Here’s a quick look at BioLineRx Ltd.’s (BLRX) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 38.47%, suggesting the stock is Neutral, with a 44.65% historical volatility rate.
The stochastic %K and %D were 28.80% and 20.31% respectively, while the average true range (ATR) was 0.1064. Based on the 14-day stochastic reading of 30.30%, the RSI (14) reading is 37.93%. On the 9-day MACD Oscillator, the stock is at 0.0121, and the 14-day reading is at -0.0503.
Analyst Ratings
In its most recent analyst report, Maxim Group raised its rating on BioLineRx Ltd. (NASDAQ: BLRX) to a Buy. Prior to this, analysts firm rated the stock as a Hold. Analysts have assigned BioLineRx Ltd. (BLRX) an Buy rating. BLRX is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is BLRX’s price target for the next 12 months?
The current consensus forecast for the stock is between $6.00 and $19.00, with a median target price of $12.50. In analyzing these forecasts, the average price target given by analysts for BioLineRx Ltd. (BLRX) is $12.50.
